| 000 | 01873 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517172704.0 | ||
| 264 | 0 | _c20180607 | |
| 008 | 201806s 0 0 eng d | ||
| 022 | _a1471-2466 | ||
| 024 | 7 |
_a10.1186/s12890-017-0462-y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBehr, Jürgen | |
| 245 | 0 | 0 |
_aExploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. _h[electronic resource] |
| 260 |
_bBMC pulmonary medicine _cSep 2017 |
||
| 300 |
_a122 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAlveolitis, Extrinsic Allergic _xcomplications |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents, Non-Steroidal _xadministration & dosage |
| 650 | 0 | 4 |
_aConnective Tissue Diseases _xcomplications |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung _xphysiopathology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPulmonary Fibrosis _xdrug therapy |
| 650 | 0 | 4 |
_aPyridones _xadministration & dosage |
| 650 | 0 | 4 | _aResearch Design |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVital Capacity _xdrug effects |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aNeuser, Petra | |
| 700 | 1 | _aPrasse, Antje | |
| 700 | 1 | _aKreuter, Michael | |
| 700 | 1 | _aRabe, Klaus | |
| 700 | 1 | _aSchade-Brittinger, Carmen | |
| 700 | 1 | _aWagner, Jasmin | |
| 700 | 1 | _aGünther, Andreas | |
| 773 | 0 |
_tBMC pulmonary medicine _gvol. 17 _gno. 1 _gp. 122 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12890-017-0462-y _zAvailable from publisher's website |
| 999 |
_c27533365 _d27533365 |
||